Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rule

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Arthritis and Rheumatism|October 2, 2002
A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritisJohn Moore, Peter Brooks, Sam Milliken, et al.
Haematologica|November 28, 2015
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.
British Journal of Haematology|December 2, 2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphomaLuca Arcaini, Thierry Lamy, Jan Walewski, et al.
Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.
Blood|November 12, 2020
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trialSteven Le Gouill, Franck Morschhauser, David Chiron, et al.
Blood|May 16, 2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinibJennifer A Woyach, Daniel Jones, Wojciech Jurczak, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Cancer Reports (Hoboken, N.J.)|July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trialCarla Casulo, Armando Santoro, Guillaume Cartron, et al.
The Lancet. Oncology|July 5, 2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialBertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Arthritis and Rheumatism|October 2, 2002
A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritisJohn Moore, Peter Brooks, Sam Milliken, et al.
Haematologica|November 28, 2015
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.
British Journal of Haematology|December 2, 2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphomaLuca Arcaini, Thierry Lamy, Jan Walewski, et al.
Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.
Blood|November 12, 2020
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trialSteven Le Gouill, Franck Morschhauser, David Chiron, et al.
Blood|May 16, 2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinibJennifer A Woyach, Daniel Jones, Wojciech Jurczak, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Cancer Reports (Hoboken, N.J.)|July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trialCarla Casulo, Armando Santoro, Guillaume Cartron, et al.
The Lancet. Oncology|July 5, 2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialBertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Pageof 8